Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs

Published:2019-05-03 Issue:5 Volume:2 Page:e192535
ISSN:2574-3805
Container-title:JAMA Network Open
language:en
Short-container-title:JAMA Netw Open

Author:

Haslam Alyson¹,Prasad Vinay²³⁴⁵

Affiliation:

1. Knight Cancer Institute, Oregon Health & Science University, Portland

2. Division of Hematology Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland

3. Department of Public Health and Preventive Medicine, Oregon Health & Science University, Portland

4. Center for Health Care Ethics, Oregon Health & Science University, Portland

5. Division of General Medicine, Department of Medicine, Oregon Health & Science University, Portland

Publisher

American Medical Association (AMA)

Subject

General Medicine

Link

http:///jamanetworkopen/article-pdf/2/5/e192535/17552975/haslam_2019_oi_190110.pdf

Reference25 articles.

1. Immune checkpoint inhibitors.;West;JAMA Oncol,2015

2. Immune checkpoint inhibitors: an innovation in immunotherapy for the treatment and management of patients with cancer.;Dine;Asia Pac J Oncol Nurs,2017

3. The immune checkpoint inhibitors: where are we now?;Webster;Nat Rev Drug Discov,2014

4. Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges.;Fukumura;Nat Rev Clin Oncol,2018

5. The immune contexture in cancer prognosis and treatment.;Fridman;Nat Rev Clin Oncol,2017

Cited by 963 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Double agents in immunotherapy: Unmasking the role of antibody drug conjugates in immune checkpoint targeting;Critical Reviews in Oncology/Hematology;2024-10

2. Immunogenic cell death-based oncolytic virus therapy: A sharp sword of tumor immunotherapy;European Journal of Pharmacology;2024-10

3. CD4 ⁺ T cells with convergent TCR recombination reprogram stroma and halt tumor progression in adoptive therapy;Science Immunology;2024-09-13

4. Identification of key immune-related genes and potential therapeutic targets in immune checkpoint inhibitor–associated myocarditis;Postgraduate Medical Journal;2024-09-10

5. A general pHLA-CD80 scaffold fusion protein to promote efficient antigen-specific T cell-based immunotherapy;Molecular Therapy: Oncology;2024-09

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3